Results 41 to 50 of about 50,964 (281)

Gene Expression Profiling Analysis Reveals Putative Phytochemotherapeutic Target for Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2019
Prostate cancer is the leading cause of cancer death among men globally, with castration development resistant contributing significantly to treatment failure and death.
Solomon Oladapo Rotimi, Oluwakemi Anuoluwapo Rotimi, Abdulkadir Ayo Salako, Paul Jibrin, Jelili Oyelade, Emeka E. J. Iweala   +5 more
doaj   +1 more source

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

New England Journal of Medicine, 2019
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.We conducted a randomized, double-blind, placebo-controlled, phase 3 trial ...
Fizazi, Karim, Shore, Neal, Tammela, Teuvo L, Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Kuss, Iris, Kappeler, Christian, Snapir, Amir, Sarapohja, Toni, Smith, Matthew R, for the ARAMIS Investigators, Aglietta, Massimo, Damiano, Rocco, Facchini, Gaetano, Gasparro, Donatello, Mucciardi, Giuseppe, Natoli, Clara, Sabbatini, Roberto, Scagliotti, Giorgio, Schepisi, Giuseppe, Serretta ,Vincenzo   +24 more
openaire   +3 more sources

[How should hormone therapy for castration-resistant prostate cancer be continued?] [PDF]

, 2012
After an average of 18-36 months under androgen suppression therapy by surgical castration, LHRH, and steroidal or non-steroidal antiandrogens, almost all patients with metastatic prostate cancer show PSA progression as a sign of androgen-independent but
Spahn, M, Krebs, M
core   +1 more source

Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer

SAGE Open Medicine, 2023
Objectives: To identify useful biomarkers by reviewing laboratory data for a predictor of the clinical course following treatment with radium-223 dichloride (Ra-223) in patients with metastatic castration-resistant prostate cancer.
Gen Kawaguchi, Kohei Akazawa, Taro Ikeda, Yohei Ikeda, Noboru Hara, Tsutomu Nishiyama   +5 more
doaj   +1 more source

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

, 2013
BACKGROUND: Median overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) was 13-16 mo in the predocetaxel era. Prognostic nomograms for survival estimation in CRPC were constructed prior to the introduction of docetaxel
Pezaro, Carmel, Omlin, Aurelius, Thompson, Emilda, Sandhu, Shahneen, Maier, Gal, de Bono, Johann, Attard, Gerhardt, Bianchini, Diletta, Olmos, David, Ferraldeschi, Roberta, Parker, Chris, Mukherji, Deborah, Mulick Cassidy, Amy   +12 more
core   +1 more source

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07) [PDF]

, 2012
The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic target. The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not
Rolf Jaggi, Denise Cotting, Cathomas, R., Brauchli, Peter, Winterhalder, R., Siciliano, D., Pless, M., Schiess, Ralph, Christian Rothermundt, Bubendorf, Lukas, Klingbiel, Dirk, Silke Gillessen, Peter Brauchli, Betticher, Daniel C, Dominik R. Berthold, Cotting, D., Richard Cathomas, Rothermundt, C., Cotting, Denise, von Moos, Roger, Brauchli, P., Berthold, D.R., Miklos Pless, Daniele Siciliano, Ralph Schiess, Winterhalder, Ralph, Gillessen, S., Jaggi, Rolf, Bubendorf, L., Betticher, D.C., Droege, Cornelia, von Moos, R., Pless, Miklos, Lukas Bubendorf, Rothermundt, Christian, Cathomas, Richard, Berthold, Dominik R, Cornelia Droege, Roger von Moos, Daniel C. Betticher, Schiess, R., Klingbiel, D., Ralph Winterhalder, Siciliano, Daniele, Jaggi, R., Droege, C., Gillessen, Silke, Dirk Klingbiel   +47 more
core   +1 more source

Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. [PDF]

PLoS ONE, 2012
The recently described transcriptomic switch to a mitosis program in castration-resistant prostate cancer (CRPC) suggests that mitotic proteins may be rationally targeted at this lethal stage of the disease.
Kanishka Sircar, Heng Huang, Limei Hu, Yuexin Liu, Jasreman Dhillon, David Cogdell, Armen Aprikian, Eleni Efstathiou, Nora Navone, Patricia Troncoso, Wei Zhang   +10 more
doaj   +1 more source

Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy

Frontiers in Oncology, 2016
Historically, androgen-deprivation therapy was the only primary treatment for metastatic prostate cancer. After prostate cancer develops into castration-resistant prostate cancer, there are a few life-prolonging drugs, including taxanes such as docetaxel
Masaki eShiota, Akira eYokomizo, Masatoshi eEto   +2 more
doaj   +1 more source

Re: The Role of MicroRNA in Castration-Resistant Prostate Cancer

, 2016
EDITORIAL COMMENT Castration-resistant prostate cancer (CRPC) arises when hormone refractory prostate cancer growth occurs in a castrate androgen level environment. Although the mechanism is not fully understood, the androgen receptor (AR) has emerged
Fehmi Narter
core   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source